New hope for Tough-to-Treat lung cancer: testing a powerful drug cocktail

NCT ID NCT05074810

Summary

This study is testing a new combination of two or three drugs for people with a specific type of lung cancer (KRAS G12C Non-Small Cell Lung Cancer). It aims to see if the combination is safe and effective, especially for patients whose cancer has progressed after previous treatments, including similar targeted drugs. The trial includes people who have and have not tried a KRAS G12C inhibitor before.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alliance Cancer Specialists,

    Horsham, Pennsylvania, 19044, United States

  • CHRU of Lille

    Lille, 59037, France

  • CHU de Liège

    Liège, 4000, Belgium

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, 44195, United States

  • Consultants in Medical Oncology & Hematology

    Broomall, Pennsylvania, 19008, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Erasmus MC

    Rotterdam, 3015 GD, Netherlands

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28007, Spain

  • Hospital Teresa Herrera (C.H.U.A.C)

    A Coruña, 15006, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, 28040, Spain

  • Hospital Universitario Virgen De La Victoria

    Málaga, 29010, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, 41009, Spain

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Foch

    Suresnes, 92150, France

  • Illinois Cancer Specialists

    Arlington Heights, Illinois, 60005, United States

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • Maryland Oncology & Hematology, P.A.

    Rockville, Maryland, 20850, United States

  • MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,

    Washington D.C., District of Columbia, 20010, United States

  • Minnesota Oncology Hematology, P.A

    Woodbury, Minnesota, 55125, United States

  • Northwest Cancer Specialists

    Vancouver, Washington, 98684, United States

  • Ohio State University Brain and Spine Hospital

    Columbus, Ohio, 43210, United States

  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Blacksburg, Virginia, 24060, United States

  • Rocky Mountain Cancer Center, LLP

    Boulder, Colorado, 80303, United States

  • Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

  • Royal Marsden Hospital

    Sutton, SM2 5PT, United Kingdom

  • Texas Oncology

    Austin, Texas, 78731, United States

  • Texas Oncology

    Longview, Texas, 75601, United States

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas, 76104, United States

  • University Hospital Gent

    Ghent, 9000, Belgium

  • University of Leicester

    Leicester, LE2 7LX, United Kingdom

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.